The Human Protein Atlas stated that the low expression of TFAM is related to unfavorable outcomes in renal cell carcinoma and ovarian cancer, but a favorable outcome in endometrial cancer (please refer to the website, Available online: https://www.proteinatlas.org/; accessed on 4 November 2021). This evidence concerns the gene TFAM and hereditary clear cell renal cell carcinoma.